Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Atherogenic dyslipidemia, a component of metabolic syndrome, is characterized by high levels of apolipoprotein B (apo B)-containing lipoproteins, including very-low-density lipoprotein remnants and small low-density lipoprotein particles, and reduced levels of high-density lipoprotein cholesterol. Although the National Cholesterol Education Program Adult Treatment Panel III includes elevations in blood pressure and plasma glucose in the definition of metabolic syndrome, the broader scope of metabolic syndrome includes proinflammatory and prothrombotic states, which derive from the secretory activity of adipose tissue. Abdominal fat can adversely affect insulin action and the disposal of glucose through an increase in the release of free fatty acid, resulting in accumulation of triglyceride in muscle and liver, thereby depressing insulin action and increasing output of apo B-containing lipoproteins. Impaired regulation of adipokines, bioactive substances secreted from adipose tissue, likely produces systemic inflammation, which can promote atherogenesis. Insulin resistance is recognized as an important metabolic defect linking the components of metabolic syndrome. One molecule that may play an important role in metabolic syndrome to regulate metabolic and vascular pathways is the peroxisome proliferator-activated receptor-gamma (PPAR-γ). Studies have established PPAR-γ deficiency as a cause of lipodystrophy and confirmed its adipogenic role. Patients with atherogenic dyslipidemia and metabolic syndrome should undergo global risk assessment for cardiovascular disease and future cardiovascular events to determine an overall treatment strategy.

Original languageEnglish (US)
JournalClinical Cornerstone
Volume8
Issue numberSUPPL. 1
DOIs
StatePublished - 2006

Fingerprint

Dyslipidemias
Insulin Resistance
PPAR gamma
Apolipoproteins B
Lipoproteins
Adipose Tissue
Insulin
Lipodystrophy
Glucose
Abdominal Fat
Adipokines
VLDL Lipoproteins
Metabolic Networks and Pathways
LDL Lipoproteins
Nonesterified Fatty Acids
HDL Cholesterol
Blood Vessels
Atherosclerosis
Triglycerides
Cardiovascular Diseases

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance. / Grundy, Scott M.

In: Clinical Cornerstone, Vol. 8, No. SUPPL. 1, 2006.

Research output: Contribution to journalArticle

@article{a72a51e90e974827b316f90fde5e7daf,
title = "Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance",
abstract = "Atherogenic dyslipidemia, a component of metabolic syndrome, is characterized by high levels of apolipoprotein B (apo B)-containing lipoproteins, including very-low-density lipoprotein remnants and small low-density lipoprotein particles, and reduced levels of high-density lipoprotein cholesterol. Although the National Cholesterol Education Program Adult Treatment Panel III includes elevations in blood pressure and plasma glucose in the definition of metabolic syndrome, the broader scope of metabolic syndrome includes proinflammatory and prothrombotic states, which derive from the secretory activity of adipose tissue. Abdominal fat can adversely affect insulin action and the disposal of glucose through an increase in the release of free fatty acid, resulting in accumulation of triglyceride in muscle and liver, thereby depressing insulin action and increasing output of apo B-containing lipoproteins. Impaired regulation of adipokines, bioactive substances secreted from adipose tissue, likely produces systemic inflammation, which can promote atherogenesis. Insulin resistance is recognized as an important metabolic defect linking the components of metabolic syndrome. One molecule that may play an important role in metabolic syndrome to regulate metabolic and vascular pathways is the peroxisome proliferator-activated receptor-gamma (PPAR-γ). Studies have established PPAR-γ deficiency as a cause of lipodystrophy and confirmed its adipogenic role. Patients with atherogenic dyslipidemia and metabolic syndrome should undergo global risk assessment for cardiovascular disease and future cardiovascular events to determine an overall treatment strategy.",
author = "Grundy, {Scott M}",
year = "2006",
doi = "10.1016/S1098-3597(06)80005-0",
language = "English (US)",
volume = "8",
journal = "Clinical Cornerstone",
issn = "1098-3597",
publisher = "Excerpta Medica",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance

AU - Grundy, Scott M

PY - 2006

Y1 - 2006

N2 - Atherogenic dyslipidemia, a component of metabolic syndrome, is characterized by high levels of apolipoprotein B (apo B)-containing lipoproteins, including very-low-density lipoprotein remnants and small low-density lipoprotein particles, and reduced levels of high-density lipoprotein cholesterol. Although the National Cholesterol Education Program Adult Treatment Panel III includes elevations in blood pressure and plasma glucose in the definition of metabolic syndrome, the broader scope of metabolic syndrome includes proinflammatory and prothrombotic states, which derive from the secretory activity of adipose tissue. Abdominal fat can adversely affect insulin action and the disposal of glucose through an increase in the release of free fatty acid, resulting in accumulation of triglyceride in muscle and liver, thereby depressing insulin action and increasing output of apo B-containing lipoproteins. Impaired regulation of adipokines, bioactive substances secreted from adipose tissue, likely produces systemic inflammation, which can promote atherogenesis. Insulin resistance is recognized as an important metabolic defect linking the components of metabolic syndrome. One molecule that may play an important role in metabolic syndrome to regulate metabolic and vascular pathways is the peroxisome proliferator-activated receptor-gamma (PPAR-γ). Studies have established PPAR-γ deficiency as a cause of lipodystrophy and confirmed its adipogenic role. Patients with atherogenic dyslipidemia and metabolic syndrome should undergo global risk assessment for cardiovascular disease and future cardiovascular events to determine an overall treatment strategy.

AB - Atherogenic dyslipidemia, a component of metabolic syndrome, is characterized by high levels of apolipoprotein B (apo B)-containing lipoproteins, including very-low-density lipoprotein remnants and small low-density lipoprotein particles, and reduced levels of high-density lipoprotein cholesterol. Although the National Cholesterol Education Program Adult Treatment Panel III includes elevations in blood pressure and plasma glucose in the definition of metabolic syndrome, the broader scope of metabolic syndrome includes proinflammatory and prothrombotic states, which derive from the secretory activity of adipose tissue. Abdominal fat can adversely affect insulin action and the disposal of glucose through an increase in the release of free fatty acid, resulting in accumulation of triglyceride in muscle and liver, thereby depressing insulin action and increasing output of apo B-containing lipoproteins. Impaired regulation of adipokines, bioactive substances secreted from adipose tissue, likely produces systemic inflammation, which can promote atherogenesis. Insulin resistance is recognized as an important metabolic defect linking the components of metabolic syndrome. One molecule that may play an important role in metabolic syndrome to regulate metabolic and vascular pathways is the peroxisome proliferator-activated receptor-gamma (PPAR-γ). Studies have established PPAR-γ deficiency as a cause of lipodystrophy and confirmed its adipogenic role. Patients with atherogenic dyslipidemia and metabolic syndrome should undergo global risk assessment for cardiovascular disease and future cardiovascular events to determine an overall treatment strategy.

UR - http://www.scopus.com/inward/record.url?scp=33747861349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747861349&partnerID=8YFLogxK

U2 - 10.1016/S1098-3597(06)80005-0

DO - 10.1016/S1098-3597(06)80005-0

M3 - Article

VL - 8

JO - Clinical Cornerstone

JF - Clinical Cornerstone

SN - 1098-3597

IS - SUPPL. 1

ER -